<DOC>
	<DOC>NCT02551172</DOC>
	<brief_summary>To investigate the efficacy and safety after administration of HCP1105 in hyperlipidemic patients with high risk for CHD.</brief_summary>
	<brief_title>Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD</brief_title>
	<detailed_description>An efficacy and safety study of HCP1105 Capsule in combined hyperlipidemic patients with high risk for Coronary Heart Disease(CHD): A randomized,double-blind, multicenter, phase 3 study.</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>age 19â‰¤ Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing History of clinically significant hypersensitivity reaction with HMGCoA reductase inhibitor and Omega3 Subject who has active liver disease and severe liver failure(Continuous elevation of AST,ALT level with unspecified cause or AST, ALT level exceeds more than three times of maximum upper range.)</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>